Received Sep 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Late 2nd and 3rd dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 70-year-old male patient who received HAB (Twinrix) for prophylaxis. Previously administered products included Twinrix (1st dose received in November 2024). On 16-SEP-2025, the patient received the 2nd dose of Twinrix. On 16-SEP-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Late 2nd and 3rd dose). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt date:18-SEP-2025 The patient received the first dose of the Twinrix vaccine in November 2024. However, the patient then they forgot to come back and gave them a 2nd dose on 16-Sep-2025.